Fig. 3From: Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paperCase 2. a Initial overall PoPS weighting NOAEL in three preclinical species; b Scenario assessment of final PoPS per biomarker fold-increase (2-, 4-, or 8-fold) and variability level (low, mid, or high) using NOAEL from the single most relevant preclinical speciesBack to article page